Millions of vulnerable heart patients have been betrayed by AstraZeneca, a pharmaceutical giant with a disturbing track record of manipulating clinical trial data to push dangerous drugs onto an unsuspecting public. 

Now, top medical experts are sounding the alarm over Brilinta (ticagrelor), a blood-thinning drug falsely marketed as a lifesaver for acute coronary syndrome. Shockingly, mounting evidence reveals that AstraZeneca misreported safety data, concealing the drug's alarming inefficacy—and even its potential to increase heart attack risks. This isn't just corporate negligence; it's a calculated deception that has put millions of lives at stake while lining the pockets of Big Pharma executives.

A history of deception: AstraZeneca's deadly track record

This isn't the first time AstraZeneca has been caught manipulating data to push a dangerous drug. The company's COVID-19 vaccine was linked to deadly blood clots, with government reports confirming 437 cases and 78 deaths in the UK alone. The same story unfolded with their ovarian cancer drug and psyche meds for children. Now, history repeats itself as Brilinta faces similar scrutiny.

Dr. Victor Serebruany, a cardiovascular pharmacology expert at Johns Hopkins University, has warned for over a decade that something was "obviously wrong" with Brilinta's trial data. "If doctors had known what happened in these trials, they would never have started using ticagrelor," he told The BMJ. Yet, AstraZeneca—backed by complicit regulators—brushed aside concerns, prioritizing profits over patient safety.

The smoking gun: Missing data and manipulated results

The BMJ's investigation uncovered damning evidence that AstraZeneca's clinical trials excluded critical platelet readings that would have exposed Brilinta's flaws. In one trial, over 60 out of 282 machine readings were mysteriously omitted from FDA submissions—readings that showed higher platelet activity, suggesting the drug failed to prevent clotting as promised.

Even more alarming, some patients experienced dramatic increases in platelet aggregation—essentially, their blood thickened dangerously, raising their risk of heart attacks and strokes. Yet, these findings were buried, allowing Brilinta to sail through approval while putting millions at risk.

The FDA and UK's MHRA have long been accused of rubber-stamping dangerous drugs under pressure from pharmaceutical lobbyists. Brilinta's approval followed the same playbook: questionable data, ignored warnings, and a rush to market. Now, with lives on the line, regulators remain eerily silent.

Meanwhile, AstraZeneca continues to gaslight the public, insisting, "We are confident in the integrity of the trials." But confidence doesn't erase the bodies piling up—patients who trusted a system rigged against them.